Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.72 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.68 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8468357 | 0.91 | AGTR1 (0.76) | AGTR1GP6AGTR2 | |
| SCHEMBL20257387 | 0.89 | AGTR1 (0.81) | AGTR1GP6AGTR2 | |
| Losartan SCHEMBL4222 | 0.88 | AGTR1 (0.86) | AGTR1GP6AGTR2 | |
| Losartan SCHEMBL4677535 | 0.87 | AGTR1 (0.84) | AGTR1GP6AGTR2 | |
| SCHEMBL3633085 | 0.87 | AGTR1 (0.78) | AGTR1GP6AGTR2 | |
| Losartan SCHEMBL14169312 | 0.86 | AGTR1 (0.80) | AGTR1GP6AGTR2 | |
| SCHEMBL20257373 | 0.85 | AGTR1 (0.76) | AGTR1GP6AGTR2 | |
| SCHEMBL23083035 | 0.85 | GP6 (0.73) | AGTR1GP6AGTR2 | |
| SCHEMBL2832525 | 0.85 | AGTR1 (0.70) | AGTR1GP6AGTR2 | |
| SCHEMBL2836742 | 0.84 | AGTR1 (0.69) | AGTR1GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126568-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERTENSION AND MANAGEMENT OF DIABETIC KIDNEY DISEASE | KANDULA MAHESH (IN) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126568-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERTENSION AND MANAGEMENT OF DIABETIC KIDNEY DISEASE | REN, SLC5A1, SLC5A2 | AGTR1 9/4885GP6 1387/4885AGTR2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.